Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $123.00

Key Points

• TransMedics Group, Inc. has received a consensus recommendation of “Moderate Buy” from nine research firms, with an average price target of $123.00 for the next year.
• In recent analyst activity, Canaccord Genuity raised its price target for the company from $129.00 to $142.00, while Oppenheimer increased its target from $130.00 to $150.00.
• The company's latest quarterly earnings showed revenue of $157.37 million, exceeding expectations, and it reported a significant year-over-year revenue increase of 37.7%.

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $122.1111.

Several research analysts have recently commented on the company. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Monday, August 25th. Piper Sandler reiterated an "overweight" rating and issued a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Morgan Stanley lifted their target price on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Canaccord Genuity Group lifted their target price on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, July 15th. Finally, Oppenheimer boosted their price objective on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research report on Tuesday, June 17th.

Insider Transactions at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider owned 13,955 shares in the company, valued at $1,950,909. The trade was a 4.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TMDX. NBC Securities Inc. acquired a new position in TransMedics Group during the 1st quarter valued at approximately $25,000. Opal Wealth Advisors LLC acquired a new position in TransMedics Group during the 2nd quarter valued at approximately $26,000. Smartleaf Asset Management LLC boosted its position in TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after acquiring an additional 135 shares during the period. Quarry LP boosted its position in TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company's stock worth $40,000 after acquiring an additional 278 shares during the period. Finally, Sound Income Strategies LLC acquired a new position in TransMedics Group during the 2nd quarter worth $48,000. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Stock Down 2.7%

TMDX stock traded down $2.89 during midday trading on Friday, hitting $104.05. 1,370,684 shares of the company's stock were exchanged, compared to its average volume of 852,488. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $169.29. The firm has a 50 day moving average price of $118.62 and a 200-day moving average price of $103.89. The stock has a market capitalization of $3.55 billion, a price-to-earnings ratio of 53.91 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.TransMedics Group's revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. On average, analysts anticipate that TransMedics Group will post 1 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.